0625 GMT - Concerns about Roche's upcoming clinical trial results persist despite improvements in its midstage pipeline over the past year, Berenberg analysts say in a note. The Swiss drugmaker's higher implemented threshold in assessing drug candidates should begin to shift the mix of its late-stage readouts toward higher return-on-investment assets, the analysts say. Berenberg analysts are less optimistic about Roche's key clinical results this year, seen as high-risk as they started before the company launched initiatives aimed at improving R&D decision-making. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
May 02, 2025 02:25 ET (06:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。